Dongsin Engineering & Construction (KOSDAQ:025950)
South Korea · Delayed Price · Currency is KRW 19,840
-150 (-0.75%)
At close: Aug 7, 2025, 3:30 PM KST
Ligand Pharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 61,784 | 68,971 | 82,744 | 50,302 | 57,433 | 35,499 | Upgrade |
Other Revenue | - | -0 | -0 | - | -0 | - | Upgrade |
| 61,784 | 68,971 | 82,744 | 50,302 | 57,433 | 35,499 | Upgrade | |
Revenue Growth (YoY) | -23.01% | -16.64% | 64.50% | -12.42% | 61.79% | 47.78% | Upgrade |
Cost of Revenue | 58,000 | 64,535 | 73,226 | 45,104 | 50,045 | 30,337 | Upgrade |
Gross Profit | 3,785 | 4,436 | 9,518 | 5,197 | 7,388 | 5,162 | Upgrade |
Selling, General & Admin | 3,699 | 2,942 | 2,509 | 3,138 | 3,492 | 2,672 | Upgrade |
Other Operating Expenses | 511.92 | 517.47 | 201.76 | 171.34 | 207.77 | 150.26 | Upgrade |
Operating Expenses | 4,581 | 3,850 | 3,177 | 3,831 | 4,306 | 2,959 | Upgrade |
Operating Income | -796.08 | 585.89 | 6,341 | 1,366 | 3,081 | 2,203 | Upgrade |
Interest Expense | -7.57 | -7.59 | -7.19 | -7.28 | -7.61 | -8.05 | Upgrade |
Interest & Investment Income | 1,852 | 1,874 | 1,881 | 549.59 | 257.32 | 329.65 | Upgrade |
Other Non Operating Income (Expenses) | -243.84 | -204.68 | 57.76 | 202.73 | -249.67 | 60.43 | Upgrade |
EBT Excluding Unusual Items | 804.09 | 2,248 | 8,273 | 2,111 | 3,081 | 2,585 | Upgrade |
Gain (Loss) on Sale of Investments | -8.32 | 86.4 | 95.09 | 4,255 | -4,595 | -5,033 | Upgrade |
Gain (Loss) on Sale of Assets | 1,704 | 1,754 | 1,088 | 1,782 | 931.3 | - | Upgrade |
Pretax Income | 2,500 | 4,088 | 9,456 | 8,149 | -582.26 | -2,448 | Upgrade |
Income Tax Expense | 1,017 | 1,087 | 1,631 | 2,080 | -290.58 | -514.08 | Upgrade |
Net Income | 1,483 | 3,001 | 7,825 | 6,069 | -291.68 | -1,934 | Upgrade |
Net Income to Common | 1,483 | 3,001 | 7,825 | 6,069 | -291.68 | -1,934 | Upgrade |
Net Income Growth | -81.89% | -61.65% | 28.94% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | 8 | Upgrade |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | 8 | Upgrade |
EPS (Basic) | 176.55 | 357.31 | 931.61 | 722.49 | -34.72 | -230.24 | Upgrade |
EPS (Diluted) | 176.55 | 357.31 | 931.61 | 722.49 | -34.72 | -230.24 | Upgrade |
EPS Growth | -81.89% | -61.65% | 28.94% | - | - | - | Upgrade |
Free Cash Flow | -6,008 | 3,575 | 6,358 | 6,565 | -6,814 | 1,722 | Upgrade |
Free Cash Flow Per Share | -715.19 | 425.57 | 756.92 | 781.58 | -811.15 | 205.01 | Upgrade |
Gross Margin | 6.13% | 6.43% | 11.50% | 10.33% | 12.86% | 14.54% | Upgrade |
Operating Margin | -1.29% | 0.85% | 7.66% | 2.72% | 5.37% | 6.20% | Upgrade |
Profit Margin | 2.40% | 4.35% | 9.46% | 12.06% | -0.51% | -5.45% | Upgrade |
Free Cash Flow Margin | -9.72% | 5.18% | 7.68% | 13.05% | -11.86% | 4.85% | Upgrade |
EBITDA | -394.41 | 1,008 | 6,839 | 1,920 | 3,706 | 2,371 | Upgrade |
EBITDA Margin | -0.64% | 1.46% | 8.27% | 3.82% | 6.45% | 6.68% | Upgrade |
D&A For EBITDA | 401.67 | 422.26 | 498.19 | 553.47 | 624.52 | 168.71 | Upgrade |
EBIT | -796.08 | 585.89 | 6,341 | 1,366 | 3,081 | 2,203 | Upgrade |
EBIT Margin | -1.29% | 0.85% | 7.66% | 2.72% | 5.37% | 6.20% | Upgrade |
Effective Tax Rate | 40.68% | 26.59% | 17.24% | 25.52% | - | - | Upgrade |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.